Overview
An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
Indication
库欣综合征的鉴别诊断,也可用于治疗。也治疗某些肾上腺皮质肿瘤引起的肾上腺功能亢进。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/08/16 | Not Applicable | Recruiting | Eleonora Seelig | ||
2023/10/30 | Phase 2 | Recruiting | |||
2023/06/27 | Early Phase 1 | Completed | Eleonora Seelig | ||
2022/02/25 | N/A | Recruiting | |||
2021/12/22 | Early Phase 1 | Completed | Eleonora Seelig | ||
2018/04/09 | Phase 4 | UNKNOWN | Centre Hospitalier Rouffach | ||
2015/04/02 | Phase 1 | Completed | |||
2014/11/21 | Phase 3 | Completed | HRA Pharma | ||
2012/08/27 | Phase 1 | Completed | |||
2012/06/15 | Phase 4 | UNKNOWN | Baker Heart Research Institute |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
HRA Pharma Rare Diseases | 76336-455 | ORAL | 250 mg in 1 1 | 2/23/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
METOPIRONE 250 metyrapone 250mg capsule bottle | 11043 | Medicine | A | 8/2/1991 |
Help Us Improve
Your feedback helps us provide better drug information and insights.